This Little-Known Industry Is Producing the Fastest-Growing Stocks

Money Morning’s Chief Investment Strategist Keith Fitz-Gerald first told his readers about the incredible profit opportunity of the human augmentation market in October 2014. Fastest Growing StocksSince then, it has provided some of the fastest-growing stocks on the market. And Fitz-Gerald sees the run continuing for years. “No matter how many times I review the data or I rearrange the puzzle, this is THE trend of the next decade,” Fitz-Gerald said. “Companies that are going to be mainstream 10 years from now are still largely under the radar – which means you want to make your move now, like a surfer does to catch the perfect wave.” And now, the mainstream media is finally catching up with Fitz-Gerald’s predictions…

The Fastest-Growing Stocks in Human Augmentation

In March, a report from the research firm MarketsandMarkets said the human augmentation market will expand at a compound annual growth rate of 43.52% from 2014 to 2020. By the end of the decade, the market will be worth $1.135 billion. Human augmentation is technology that enhances human capabilities or productivity. These technologies include implants, orthotic devices, limb devices, and even wearable virtual reality devices. Fastest growing stocksFitz-Gerald was one of the first experts talking about the potential of the market. Now mainstream media has caught on. Both CNBC and FOX News have covered the market, detailing the MarketsandMarkets report. Dozens of other outlets soon followed. “That tells me that there’s an awakening underway. The dawning realization that this is not merely a science fiction indulgence makes the Human Augmentation market an even more viable investment opportunity,” Fitz-Gerald said. “This also suggests you can expect the tone of the coverage to shift even more rapidly as more investors discover what we already know.” We’ve already seen that publicity translate into major gains for human augmentation stocks. Take a look at the gains of these three fast-growing stocks that Fitz-Gerald has detailed:

  • Synaptics Inc. (Nasdaq: SYNA) develops custom designed user interface solutions for mobile devices. The technology has wide-ranging applications and will help bridge the gap between augmentation-enhanced bodies and the human limitations we all face. Since the start of 2013, SYNA stock has jumped 189%.
  • Vuzix Corp. (Nasdaq: VUZI) designs, manufactures, and sells computer display technology and software. The company is best known for the M100 Smart Glasses, which are android-based wearable computers. In the last year, VUZI stock has climbed nearly 90%.
  • Infinity Augmented Reality Inc.’s (OTCMKTS: ALSO) software allows users to experience the real world through digital image overlay, video, and sound as it’s accessed from a pair of digital glasses. The stock is extremely speculative at just $0.09 per share, but it is up 50% in 2015 alone.

And while those are some of the fastest-growing stocks on the market, they’re nothing compared to where Fitz-Gerald’s favorite stock in this industry is headed... This tech stock has already jumped 46% since he recommended it in October. And he says it could soar another 987% in the next five years. "My trip to this tiny company was quite simply the most inspirational visit I've ever made to any company… in any industry… anywhere in the world," he said.

The Best Human-Augmentation Stock to Buy Now

Ekso Bionics Holdings Inc. (OTCBB: EKSO) develops robotic exoskeletons. They're suits that allow people with severe mobility issues, stroke victims, and those with spinal trauma to walk again.

Ekso's products are also unique. Normally, these suits require hours of learning and fitting. But Ekso's products are much easier to use. In fact, Fitz-Gerald said, the demonstrator took less than five minutes to get acclimated. The suits also adapt to different wearers with just the push of a button.

Keith's EKSO Projections

  • EKSO is able to capture 25% market share, resulting in $450 million of revenue.
  • Assume an 11.6% profit margin (the average of its industry: Medical Instruments and Supplies).
  • Therefore, the company would achieve (from the medical devices segment alone) net income of $52.2 million.
  • Assuming no additional share dilution, there would be 78.61 million shares outstanding.
  • Therefore, earnings of $0.664 per share.
  • PE ratio of 32.9 (based on industry average)
  • Therefore, a potential share price of $21.85 by 2020, which represents a 987% gain from today's price of $2.01/share.

The products’ applications stretch far beyond the medical field. Government agencies and contractors have been working with Ekso to develop devices for soldiers that will increase load-carrying capacity.

The company has already licensed technology to Lockheed Martin Corp. (NYSE: LMT) and has received more than $35 million in research grants from the Department of Defense.

“From the first moment it came to my attention, I've been as consistent as I have been emphatic – EKSO stock is a ‘buy’ despite the volatility and price drift in recent months that have given many investors pause,” Fitz-Gerald said.

And the MarketsandMarkets report had a detailed section explaining Ekso’s business. So if Wall Street didn’t know about EKSO stock before, they do now.

Ekso’s latest earnings report was a huge success as well. For Q4 2014, revenue jumped 87.5% to $1.5 million.

“The real winners usually have great specificity and a narrow product/market concentration,” Fitz-Gerald said. “So you see those gains translate into a broad base at every level of operations. This is where EKSO stands out.”

Last quarter, revenue from medical devices climbed 80% and revenue from engineering services was up 100%.

“Operating expenses were up 106% to $5.4 million, but even that's good news when put in context,” Fitz-Gerald said. “The increase was thanks mostly to labor-related costs: EKSO is expanding its work force in preparation for a surge in demand for its products.”

EKSO opened today at just $2.01 per share – so it’s still a speculative play. Fitz-Gerald advises using dollar-cost averaging to invest in EKSO stock. That means buying 25% of your desired position at a time until reaching your target shareholding. He recommends minimizing risk by putting no more than 2% of a portfolio into Ekso.

Investors should also plan on holding EKSO for at least 24 months. Any short-term volatility will be worth it. Right now, Fitz-Gerald has a price target of $21.85 for EKSO stock by 2020.

"EKSO is not just a great investment for your financial future," Fitz-Gerald said. "It's a great investment for the future of humankind."

The Bottom Line: Human augmentation is producing some of the fastest-growing stocks on the market. The market is expanding at a compound annual growth rate of 43.5% and will be worth $1.1 billion by 2020. While stocks like SYNA, VUZI, and ALSO are all up double digits, EKSO has a chance to bring profits of 1,038% in the next five years.

Make 2015 Your Wealthiest Year Yet… It just takes four easy steps to get started. We tell you what they are in our money-making guide for 2015. You'll get the three bad investing habits to dump immediately and the single most effective strategy to maximize returns. BONUS: You'll find out five stocks that will get you started on the road to wealth…